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Abstract: Little epidermiological data is available on the prevalence of HIV, Hepatitis B and C, Co-and or triple infection 
during pregnancy in Cameroon as well as many other resource limited settings. HIV and Hepatitis B and C are major public 
health concerns world wide. Our study aimed at assessing the seroprevalence of Hepatitis B and C amongst HIV infected 
pregnant women in Buea, located in the Southwest region of Cameroon. A Cross-sectional study on consented pregnant 
women were conducted from March 2015 to August 2015. HIV-1 infections were detected using the national HIV-1 test 
algorithms. Hepatitis B surface antigen (HBsAg), anti-HBe and anti- Hepatitis C (anti-HCV) were detected using Enzyme 
linked Immunosorbent Assays (ELISAs). Of the 1230 recruited pregnant women, 97/1230 (7.8%) (95% CI: 3.5, 29.0%) were 
confirmed HIV-1 positive. HIV/HBV co-infection were observed in 14/97 (14.4%) (95% CI: 39.8, 100%), whilst 11/97 
(11.3 %; 95% CI: 27.5, 100%) were HIV/HCV co-infections. Two HIV-infected pregnant women (8/97(8.2%; 95% CI: 0.1, 
17.2%)) were HIV/HBV/HCV triple-infected. Anti-HBc was detected in all HBV-infected pregnant women (14/14; (100.0%)) 
(95.0% CI: 39.8, 100.0%). Seropositivity for HIV-1 was higher (37%) amongst subjects aged between 32-37 years, whilst none 
was found above 40. From our results we conclude that Co- and triple infections of HIV, Hepatitis B and C were present 
amongst pregnant women in Buea. Epidemiological data generated from this study are limited due to the existence of triple 
infected. It will therefore serve as a guide to the government policies to reinforce screening, treatment and prevention 
strategies, through its Mother–to-Child–transmission (pMTCT) Programme nationwide. 
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1. Introduction 
According to the World Health Organization (WHO), HIV-1 
accounts for approximately 35.6 million global infections [2]. 
Hepatitis B virus (HBV) and Hepatitis C virus (HCV) account 
for around 240 million and 170 million chronic infections, 
respectively. HBV and HCV are the most common causes of 
viral hepatitis infections in Cameroon [1-2]. Acute viral 
infection is characterized by nausea, malaise, abdominal pain 
and jaundice. In most cases the infection is asymptomatic, 
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while the persistence of viremia after a period of six months 
leads to chronic hepatitis. The latter remains silent and is the 
main risk factor for end-stage liver diseases [4]. 
In the HIV-infected population, HBV and HCV co-
infection numbers vary from 2-4 and 3-4 million, 
respectively [3-5]. It is estimated that one-third of deaths 
recorded in HIV-infected patients are associated with severe 
liver fibrosis/cirrhosis or hepatotoxicity associated with 
antiretroviral therapy (ART). Little is known about HIV, 
HBV and HCV triple infections. The rate of co-infections 
and triple infections in HIV, HBV and HCV patients varies 
worldwide and depends on the different geographic regions, 
risk groups and exposure involved [7-11]. The presence of 
co- and or triple infections of these viruses are of major 
public health concern, owed to their high morbidity and 
mortality rate [12-13]. 
Although the routine screening of HBV in pregnant 
women has been recommended by the WHO, implementation 
remains limited due to the high costs associated and required 
infrastructure needed in resource-limited settings, such as 
Cameroon. 
National studies performed in different settings have 
recorded high prevalence rates of HIV, HBV and HCV 
mono-infections, ranging from 4.0% to 6.9%, 8.0% to 12.0% 
and 3.9% to 13.0%, respectively [14 17]. General global 
prevalence of HIV/HBV co-infection rates ranges from   
10.0% to 12.0%, whilst HIV/HCV co-infection has recorded 
3.0% to 5.0% prevalence rates [17-18]. The rate of HIV/HBV 
and HIV/HCV co-infection remains a concern in the 
Cameroonian antenatal population. Data on triple infection is 
scarce. This study aimed at assessing the seroprevalence of 
HIV, HBV and HCV amongst pregnant women. This study 
re-inforces the need for compulsory background screening 
and assisting the implementation of HBV prevention of 
Mother-to-Child transmission [PMTCT] programs. 
1.1. Study Design 
This was a cross-sectional descriptive study of a cohort of 
pregnant women visiting the various Antenatal Clinics 
(ANC) in Buea from March 2014 to August 2014. A total of 
409 participants were enrolled. 
1.2. Study Setting 
Buea, capital of the southwest region of Cameroon, is a 
semi urban city inhabited by about 200 000 multicultural 
individuals. The city was reported to have the highest 
prevalence of HIV infection among pregnant women 
attending ANC, which varied between 7.8%-8.0% in the 
years 2000, 2002 and 2011 [8]. 
2. Method 
In this study, 1230 consenting women were enrolled. 
Socio-demographic and explanatory variables were collected 
using a structured questionnaire. Venous blood was collected 
from each participant into Serum separation tubes (SST). 
Serum samples were stored at -20°C until use. The samples 
were transported and analyzed to the Center for the Study 
and Control of communicable Diseases of the Faculty of 
Medicine and Biomedical Sciences of the University of 
Yaoundé 1 (CSCCD/FMBS). HIV testing was performed 
following the national HIV testing algorithms, which 
includes 2 rapid test kits (Abbott Determine, France) and 
(SDBioline HIV1 / 2, Germany), followed with a 
confirmation test using a 3
rd
 generation Enzyme linked 
Immunosorbent Assay (ELISA) (Murex version 1.3, France). 
HBV and HCV serological markers were detected using a 
rapid detection kit (Acon, France) (for HBsAg and HCV 
antibodies) and confirmed with a 3
rd
 generation Ultra 
Monolisa ELISA kit for HBsAg, anti-HBe and anti-HCV 
(Bio-Rad laboratories, France). 
Statistical analysis 
Statistical analysis was performed using SPSS version 
14.0. The Pearson chi-square analysis was used for the 
distribution of HIV-1 infection among the various age 
groups. Descriptive statistics and binary logistic regression of 
Fischer’s exact were used. We considered a 95% confidence 
interval, 5% margin of error, 50% proportion and 5% 
contingency to justify our sample size. 
3. Results 
3.1. Socio-Demographic Characteristics 
A total of 1230 pregnant women were included in the 
study. The mean age of the study participants was 25.72 
(SD.±5.14) years old. Table 1 shows detailed socio-
demographics of study participants. 
Table 1. Socio-demographic characteristics. 
Characteristics Study population, n/N (%) 
HIV Status  
Positive 97/1230 (7.8%) 
Negative 1000/1230 (81.2%) 
Marital Status  
Single 700/1230 (56%) 
Married 530/1230 (44%) 
Educational levels  
Formal 900/1230 (73%) 
Non formal 330/1230 (27%) 
Table 2. Age distribution and prevalence of HBV, HCV Co-Infection among 
HIV-1 infected pregnant women. 
Characteristic HIV-1 infected pregnant women, n/N (%) 
Mean age: 25(SD.±5.14)  
20-25 16/79 (20%) 
26-31 18/97 (18%) 
32-37 24/97 (30%) 
38-43 19/97 (24%) 
>40 Noon /97 (0%) 
Co-infection  
HIV/HBV 14/97 (17.8%) 
HIV/HCV 11/97 (11.2%) 
Triple-infection  
HIV/HBV/HCV 8/97 (8.2%) 
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3.2. Prevalence of HIV, HBV and HCV Co - infection 
Of the 1230 recruited pregnant women, 97/1230 (7.8%) 
(95%CI: 3.5, 29.0%) were confirmed HIV-1 positive. 
HIV/HBV co-infection were observed in 14/97 (14.4%) 
(95%CI: 39.8, 100%), whilst 11/97 (11.3%; 95%CI: 27.5, 
100%) were HIV/HCV co-infections. Two HIV-infected 
pregnant women (8/97(8.2%; 95%CI: 0.1, 17.2%) were 
HIV/HBV/HCV triple-infected. Anti-HBc was detected in all 
HBV-infected pregnant women (14/14; (100.0%) (95.0%CI: 
39.8, 100.0%). Seropositivity for HIV-1 was higher (37%) 
amongst subjects aged between 32-37 years, whilst none was 
found above 40. Prevalence of co- and triple infections (with 
HIV, HBV and HCV) did not vary with age. 
4. Discussion 
The purpose of this study was to record and step-up 
epidemiological data on co-and/or triple infection of HIV, 
HBV and HCV amongst HIV-1 infected pregnant women 
attending antenatal clinics in the south west regional capital 
of Buea, Cameroon. 
The mean age of the study participants was 25.72 
[SD.±5.14]. In this study, 7.8% of the pregnant women were 
seropositive for HIV-1 and none for HIV-2. This suggests 
that HIV-1 is prevalent in this region, which concords with 
its predominance worldwide [1-3]. The HIV seropositivity 
was higher [23.2%] among the subjects aged between 25 and 
40 years, whilst none was found above 40 years. The high 
HIV-1 prevalence in this group could be attributed to the fact 
that women at this age are more likely exposed due to high 
sexual activities and unprotected sex in an effort to fall 
pregnant and have children. 
The overall results of this study indicate a high prevalence 
of HIV co-and triple infections of Hepatitis B and C among 
pregnant women [12.5%,9.6% and 6.6%]in Buea. However, 
other studies reporting on the prevalence of HBsAg among 
HIV-infected patients have described a HBsAg prevalence 
rate varying from 5.4% to 6.0% among pregnant women in 
rural settings and from 7.0% to 12.5% in urban settings [4-7]. 
The high HBsAg rate in urban settings could be a result of 
improved laboratory facilities, increased awareness and 
perhaps success in the implementation of systematic HBV 
screening of pregnant women in PMTCT program whose 
implementation in the rural areas is below 2% [7-9]. 
The high prevalence of HBsAg observed in this study 
among pregnant women could be an indication that pregnant 
women serve as a very important reservoir to fuel the HBV 
epidemic in the Cameroonian general population. However, 
previous studies indicate that in areas of high HBV 
prevalence (i.e. ≥ 8%) like Cameroon, horizontal 
transmission during childhood is predominant [10-12]. 
Heterogeneity in religion, culture and practices, and a high 
HIV burden are factors that might influence the HBV and 
HCV epidemiology in sub-Saharan Africa (SSA). From our 
results, the prevalence of HIV/HBV and HIV/HCV co-
infections were 12.5% and 9.3% respectively. 
HIV-1 has been shown to promote HBV and HCV viral 
replication and viral reactivation leading to an increased 
progression towards fibrosis and liver cirrhosis [13–15]. 
These results, though high, are similar to those reported by 
Flambo et al [2014] [13-16] and Fomulu et al [2013] [16-18]. 
However, our results are somehow contradictory to 
Gutierrez, et al [2012] [12-18]. This contrast could be due to 
the fact that no pregnant women were triple infected. 
Moreover, the clearly defined wide geographical variation of 
HIV-1 seroprevalence also defines the varying co and triple 
infections rate amongst pregnant women within Cameroon. 
The variations may be a reflection of the differences in 
sexual practices and behavior, awareness of HIV infection 
and testing, sociocultural practices and accessibility to 
healthcare. 
From this study, the prevalence of HIV/HBV co-infections 
among HIV-infected pregnant women in Buea is 12.5%. This 
reported prevalence is higher than reports from other studies 
carried out within SSA countries, like the 4.9% reported by 
Baye [2014] [12] among HIV-infected patients in Dessie 
Referral Hospital, Ethiopia. Opaleye et al., [2010] [13-15] 
reported a prevalence rate of 5.4% among blood donors in 
Benin City, Nigeria. The differences and low prevalence rates 
recorded in these studies could be attributed to the difference 
in patient selection. The HIV/HBV co-infection rate is high 
[12.5%] in this study, and is comparable to what is found by 
other investigators in neighboring countries like Nigeria (Obi 
et al., 2007 [20]; Callebeng et al., 2006 [14] Tremeau-
Bravard et al., 2012 [17-20]. In a study by Tremeau-Bravard 
et al., [2012] a 7.9% HIV/HBV co-infection rate was 
reported. HBV prevalence among pregnant women varies 
from one country to another, and mostly ranges between 6% 
and 9.5% [22-24]. These results will be used to establish 
appropriate management and preventive policies for women 
attending antenatal clinics in Cameroon. 
From the above discussion, we therefore propose that, the 
Government and Ministry of Public Health should rely on 
surveillance data to track the incidence of acute infection 
amongst the three viruses. Development and evaluation of 
programs and policies designed to prevent infection and 
minimize the public health impact of viral hepatitis, in HIV 
infected population. 
Effective systems for conducting surveillance for chronic 
HBV and HCV infections are needed to ensure accurate 
reporting of all cases and to support and evaluate prevention 
activities. The Ministry Public Health should strengthen 
guidelines for the Universal screening of all pregnant women 
in both the rural and urban regions in the country through the 
PMTCT programme for hepatitis nationwide. 
5. Limitations 
Our results had as main bias that pregnant HIV-infected 
women with acute or chronic viral hepatitis represent only 
those relatively few infected persons who were detected, and 
diagnosed. It should also be noted that, most HIV-infected 
pregnant women with viral hepatitis infections are not 
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reported, resulting in under estimates and variable data 
quality. Moreover, viral characterization was not performed 
owed to the unavailability of infrastructures. Also, although 
HBV serological assays reported on the presence of active 
HBV infection, confirmation with nucleic acid testing (NAT) 
would have been useful to demarcate active infection from 
occult infection. The strengthen of this study is the fact that it 
is the first to demonstrate the presence of triple infections of 
HIV, HBV and HCV amongst pregnant women in Cameroon. 
6. Conclusion 
This study described the presence of HIV/HBV, HIV/HCV 
co-infections and triple co-infections amongst pregnant 
women in Buea, Cameroon. More epidemiological data are 
needed to guide future government policies aimed at 
reinforcing screening, treatment and prevention strategies in 
the antenatal population. 
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